Table 1.
US societal health utilities for patients with chronic myeloid leukemia derived from the published literature
| Disease status | QALYs* (range for sensitivity analyses) | Description |
|---|---|---|
| CP, responding to treatment | 0.89 (0.78–0.94) | CCyR |
| CP, not responding to treatment | 0.75 (0.57–0.85) | At diagnosis; or lack of CCyR leading to switch |
| AP, responding to treatment | 0.79 (0.62–0.88) | Szabo 2010 |
| BP, responding to treatment | 0.59 (0.4–0.72) | Szabo 2010 |
| BP, not responding to treatment | 0.22 (0.07–0.34) | Szabo 2010 |
| Treatment changed because of serious adverse events | 0.58 (0.38–0.76) | Switch from first TKI to another |
| Allogeneic transplantation (within 1 y) | 0.6 (0.51–0.69) | Szabo 2010 |
| Allogeneic transplantation (after 1 y) | 0.85 (0.723–0.978) | Szabo 2010 |
| MMR | 0.9 (0.765–0.99) | Szabo 2010 |
| Death | 0 | Anchor |
* Quality-adjusted life-years (QALYs) are extracted from Szabo et al. (2010). They relate to this analysis as the health utility weights derived from the EQ5D index from the US societal perspective and represent measures of effectiveness in this analysis. In general, QALYs range from 0.0 to 1.0, where 0.0 represents death and 1.0 represents full health over one year. This range should be incremental, such that 0.5 QALY is exactly ½ of full health. AP = accelerated phase; BP = blast phase; CP = chronic phase; MMR = major molecular response; QALYs = quality-adjusted life-years; TKI = tyrosine kinase inhibitor.